WuXi Biologics (Cayman) 주식 (OTC: WXXWY)

에 대한 최신 뉴스 WuXi Biologics (Cayman) (OTC:WXXWY) 주식

WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has a global revenue of CNY 17 billion. North America represented 47.4% of total revenue in 2023. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual sourcing strategy by providing drug products and drug substance manufacturing.

News

Politics

Markets

PHBBF

WUXAY

WXXWY

도널드 트럼프 대통령은 제약 회사들에게 제조를 미국으로 되돌려 놓지 않으면 관세에 직면할 것이라는 엄중한 경고를 했다고 보도되었다. 금요일(21일) 블룸버그 통신에 따르면 트럼프 대통령은 비공개 회의에서 제약사들에 임박한 관세에 대해 경고하며 해외 생산을 미국으로 서둘러 이전할 것을 촉구했다. 

트럼프, 거대 제약사에 경고 &#34;미국으로 생산 이전 안 하면 관세 부과&#34;

WUXI BIOLOGICS UNSP/ADR by Wuxi Biologics (Cayman) Inc

WuXi Biologics (Cayman) Inc

Legendary investor Warren Buffett released the latest Berkshire Hathaway Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>)(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) shareholder letter over the weekend.
The <a href="https://www.benzinga.com/trading-ideas/25/02/43893285/warren-buffetts-annual-shareholder-letter-arrives-saturday-could-investors-get-updates-on-apple-succession-new-investments">highly anticipated release </a>included many updates and comments on the state of the market and the company's businesses, but one missing item could become a big topic of discussion.
What Happened: Berkshire Hathaway's <a href="https://www.benzinga.com/25/02/43900955/berkshire-hathaways-q4-profits-soar-71-warren-buffett-says-his-firm-has-paid-more-taxes-than-tech-titans-in-trillions">newest shareholder letter </a>highlighted the company's different business segments, including the strength of the insurance sector.
Across Berkshire Hathaway there are 189 operating businesses, which collectively employ nearly 400,000 people.
As part of Berkshire Hathaway&#8217;s annual report, the letter omitted a line on the company's diversity that had been in past shareholder letters, as <a href="https://nypost.com/2025/02/23/business/buffetts-berkshire-hathaway-removes-diversity-and-inclusion-from-annual-report/">reported </a>by the New York Post.
The previous report said Berkshire Hathaway's hiring practices "intended to identify qualified candidates and promote diversity and inclusion in the workforce."
This year's letter stopped that line after the word candidates, omitting the diversity and inclusion line.
Berkshire Hathaway did not respond to a request for comment by Benzinga at the time of writing.
In May 2024, Berkshire Hathaway shareholders voted down a proposal for the company to disclose more about its efforts to promote DEI. The company's board of directors opposed the proposal.
You may not be a billionaire like Warren Buffett, but you can uncover hidden gems in the stock market using our proprietary data and pattern recognition — <a href="https://www.benzinga.com/trading-ideas/25/02/43900861/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-54">check out five stocks flying under the radar that deserve your attention.</a>
 Why It's Important: The removal of the diversity and inclusion line could be Berkshire Hathaway following many other companies that have changed their hiring policies and wording to omit terms like diversity and inclusion in the current Donald Trump White House administration era.
Trump has fought to eliminate DEI, a common acronym for diversity, equity and inclusion, across businesses and federal government agencies. DEI is often used by companies to promote fair hiring policies to also include people who are underrepresented in the workforce and are more likely to be discriminated against in the hiring process.
Another explanation could be Berkshire Hathaway giving the power to their operating units to decide what is best for their own hiring processes. This could be a way to not be targeted by Trump and also let its businesses hire based on their own terms.
One of Berkshire Hathaway's largest portfolio companies has <a href="https://www.benzinga.com/news/25/02/43737860/coca-cola-pepsico-adjust-dei-policies-following-trump-executive-order-report">changed its DEI programs</a> and hiring practices. Beverage giant Coca-Cola Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) was expected to revise its DEI policy to adhere to a new White House mandate that affects beverage services on military bases and other government properties.
The beverage company recently said that its cooperation with DEI mandates for federal contractors<a href="https://www.benzinga.com/25/02/43881721/coca-cola-warns-shortage-of-diverse-talent-could-harm-future-success"> could hurt </a>the company's business.
"If we are unable to attract or retain specialized talent or top talent with diverse perspectives, experiences and backgrounds that reflect the broad range of consumers and markets we serve around the world, our business could be negatively affected," Coca-Cola said in its recent risk factors of a financial filing.
Berkshire Hathaway owns 400 million Coca-Cola shares, representing around 9.3% of the beverage company.
Changing DEI policies and wording on websites and in materials is becoming more common for companies in the Trump era.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/education/25/01/42832123/warren-buffett-beats-sp-500-in-2024-how-oracle-of-omahas-returns-compare-over-past-20-years">Warren Buffett Beats S&amp;P 500 In 2024, How Oracle Of Omaha&#8217;s Returns Compare Over Past 20 Years</a></li>
</ul>
Photo: Buffett, Courtesy of the White House/Public Domain; Berkshire Hathaway, Shutterstock

Warren Buffett Backtracks On DEI? Berkshire Hathaway Shareholder Letter Removes Diversity Mention

In the preceding three months, 6 analysts have released ratings for EPAM Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPAM#NYSE">EPAM</a>), presenting a wide array of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $274.0, a high estimate of $295.00, and a low estimate of $250.00. This upward trend is apparent, with the current average reflecting a 5.38% increase from the previous average price target of $260.00.
<img src="https://www.benzinga.com/files/images/story/2025/1740423662_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of EPAM Sys among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Divya Goyal</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$250.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Mayank Tandon</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$265.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>James Faucette</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$256.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Surinder Thind</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$288.00</td>
<td>$305.00</td>
</tr>
<tr>
<td>Ramsey El-Assal</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$290.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>James Schneider</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$295.00</td>
<td>$235.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to EPAM Sys. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of EPAM Sys compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of EPAM Sys's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of EPAM Sys's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EPAM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on EPAM Sys analyst ratings.</a>
<h2>Delving into EPAM Sys's Background</h2>
EPAM Systems is a global IT services firm that offers platform engineering, software development, and consulting services. EPAM's largest market is North America, which represents approximately 60% of revenue. Offerings span assisting companies with new technologies, such as artificial intelligence, virtual reality, and robotics.
<h3>Financial Milestones: EPAM Sys's Journey</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, EPAM Sys showcased positive performance, achieving a revenue growth rate of 6.92% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: EPAM Sys's net margin excels beyond industry benchmarks, reaching 8.27%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): EPAM Sys's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.88%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): EPAM Sys's ROA stands out, surpassing industry averages. With an impressive ROA of 2.24%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.04.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

EPAM

Analyst Expectations For EPAM Sys's Future

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Allegro Microsystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGM#NASDAQ">ALGM</a>) in the last three months.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Allegro Microsystems and provided 12-month price targets. The average target is $28.0, accompanied by a high estimate of $30.00 and a low estimate of $23.00. Witnessing a positive shift, the current average has risen by 8.53% from the previous average price target of $25.80.
<img src="https://www.benzinga.com/files/images/story/2025/1740423653_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Allegro Microsystems among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quinn Bolton</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$23.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Quinn Bolton</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Blayne Curtis</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$30.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Joseph Quatrochi</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$27.00</td>
<td>$23.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Allegro Microsystems. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Allegro Microsystems compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Capture valuable insights into Allegro Microsystems's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ALGM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Allegro Microsystems analyst ratings.</a>
<h2>Discovering Allegro Microsystems: A Closer Look</h2>
Allegro Microsystems Inc is a designer, developer, fabless manufacturer, and marketer of sensor ICs and application-specific analog power ICs for automotive and industrial markets. Its Sensor IC allows customers to precisely measure motion, speed, position, and current, and Power ICs include high-temperature and high-voltage capable motor drivers, power management, and LED driver ICs. Its products are divided into three categories such as SENSE which includes Current Sensors, Switches and Latches, and Interface ICs among others; REGULATE which includes Regulators, ClearPower Modules, and LED Drivers; and DRIVE which includes BLDC Drivers, Brush DC, and others. Key revenue for the company is generated from Greater China and the rest from the United States, Japan, Europe, and other regions.
<h3>Allegro Microsystems's Financial Performance</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Negative Revenue Trend: Examining Allegro Microsystems's financials over 3 months reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -30.24% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -3.86%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Allegro Microsystems's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -0.73%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -0.47%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Allegro Microsystems's debt-to-equity ratio stands notably higher than the industry average, reaching 0.43. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Significance of Analyst Ratings Explained</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALGM

What Analysts Are Saying About Allegro Microsystems Stock

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Consolidated Edison (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ED#NYSE">ED</a>) in the last three months.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Consolidated Edison and provided 12-month price targets. The average target is $96.6, accompanied by a high estimate of $101.00 and a low estimate of $92.00. This upward trend is evident, with the current average reflecting a 2.11% increase from the previous average price target of $94.60.
<img src="https://www.benzinga.com/files/images/story/2025/1740423647_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Consolidated Edison among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Weisel</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$101.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Nicholas Campanella</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$95.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Anthony Crowdell</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$95.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Nicholas Campanella</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$92.00</td>
<td>$99.00</td>
</tr>
<tr>
<td>Andrew Weisel</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$100.00</td>
<td>$90.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Consolidated Edison. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Consolidated Edison compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Consolidated Edison's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Consolidated Edison's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ED/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Consolidated Edison analyst ratings.</a>
<h2>Delving into Consolidated Edison's Background</h2>
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange &amp; Rockland, or O&amp;R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities generate nearly all of Con Ed's earnings following the sale of its clean energy business to RWE in early 2023.
<h3>Consolidated Edison's Financial Performance</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Consolidated Edison's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 6.53%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Utilities sector.
Net Margin: Consolidated Edison's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 8.45%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Consolidated Edison's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 1.41%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Consolidated Edison's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.45%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Consolidated Edison's debt-to-equity ratio is below the industry average. With a ratio of 1.27, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Consolidated Edison Stock: Analyst Perspectives (5 Ratings)

Investors with a lot of money to spend have taken a bullish stance on Coherent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COHR#NYSE">COHR</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with COHR, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 10 uncommon options trades for Coherent.
This isn't normal.
The overall sentiment of these big-money traders is split between 50% bullish and 20%, bearish.
Out of all of the special options we uncovered, 4 are puts, for a total amount of $453,300, and 6 are calls, for a total amount of $223,669.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $50.0 to $100.0 for Coherent over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Coherent's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Coherent's whale activity within a strike price range from $50.0 to $100.0 in the last 30 days. 
<h3>Coherent Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740423640_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>COHR</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$27.6</td>
<td>$27.0</td>
<td>$27.25</td>
<td>$100.00</td>
<td>$272.5K</td>
<td align="right">509</td>
<td align="right">75</td>
</tr>
<tr>
<td>COHR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$28.5</td>
<td>$28.0</td>
<td>$28.0</td>
<td>$100.00</td>
<td>$70.0K</td>
<td align="right">509</td>
<td align="right">0</td>
</tr>
<tr>
<td>COHR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$30.0</td>
<td>$27.6</td>
<td>$27.6</td>
<td>$100.00</td>
<td>$69.0K</td>
<td align="right">509</td>
<td align="right">75</td>
</tr>
<tr>
<td>COHR</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$15.4</td>
<td>$14.7</td>
<td>$15.0</td>
<td>$90.00</td>
<td>$60.0K</td>
<td align="right">118</td>
<td align="right">100</td>
</tr>
<tr>
<td>COHR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$45.4</td>
<td>$41.5</td>
<td>$43.99</td>
<td>$50.00</td>
<td>$48.3K</td>
<td align="right">29</td>
<td align="right">0</td>
</tr>
</tbody>
</table>

<h3>About Coherent</h3>
Coherent Corp engaged in materials, networking, and lasers, is a vertically integrated manufacturing company that develops, manufactures, and markets engineered materials, optoelectronic components and devices, and lasers for use in the industrial, communications, electronics and instrumentation markets. The firm operates in three segments Networking, Materials, and Lasers Segment. It generates maximum revenue from Networking segment. The company geographically operates in North America. Europe, China, Japan and Rest of the world.
In light of the recent options history for Coherent, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Coherent</h3>
<ul>
<li>With a volume of 1,236,030, the price of COHR is up 0.56% at $83.1. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 70 days.</li>
</ul>
<h3>What The Experts Say On Coherent</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $115.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Morgan Stanley continues to hold a Equal-Weight rating for Coherent, targeting a price of $115. 
&#x2A; Maintaining their stance, an analyst from Raymond James continues to hold a Outperform rating for Coherent, targeting a price of $110. 
&#x2A; An analyst from Rosenblatt persists with their Neutral rating on Coherent, maintaining a target price of $115. 
&#x2A; An analyst from Needham persists with their Buy rating on Coherent, maintaining a target price of $125. 
&#x2A; An analyst from Morgan Stanley persists with their Equal-Weight rating on Coherent, maintaining a target price of $110. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Coherent, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Options

COHR

Spotlight on Coherent: Analyzing the Surge in Options Activity

12 analysts have shared their evaluations of Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $176.67, a high estimate of $209.00, and a low estimate of $155.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 1.35%. 
<img src="https://www.benzinga.com/files/images/story/2025/1740423636_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Procter &amp; Gamble. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Korinne Wolfmeyer</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$172.00</td>
<td>$173.00</td>
</tr>
<tr>
<td>Nik Modi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$164.00</td>
<td>$164.00</td>
</tr>
<tr>
<td>Mark Astrachan</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$165.00</td>
<td>$161.00</td>
</tr>
<tr>
<td>Chris Carey</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$180.00</td>
<td>$176.00</td>
</tr>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$159.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$209.00</td>
<td>$209.00</td>
</tr>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$155.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Mark Astrachan</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$161.00</td>
<td>$167.00</td>
</tr>
<tr>
<td>Peter Grom</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$189.00</td>
<td>$196.00</td>
</tr>
<tr>
<td>Andrea Teixeira</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$181.00</td>
<td>$186.00</td>
</tr>
<tr>
<td>Chris Carey</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$176.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$209.00</td>
<td>$209.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Procter &amp; Gamble. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Procter &amp; Gamble compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Procter &amp; Gamble's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Procter &amp; Gamble's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/PG/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Procter &amp; Gamble analyst ratings.</a>
<h2>Discovering Procter &amp; Gamble: A Closer Look</h2>
Since its founding in 1837, Procter &amp; Gamble has become one of the world's largest consumer product manufacturers, with annual sales approaching $85 billion. It operates with a lineup of leading brands, including more than 20 that generate north of $1 billion each in annual global sales, such as Tide laundry detergent, Charmin toilet paper, Pantene shampoo, and Pampers diapers. Sales outside its home turf represent more than half of the firm's consolidated total.
<h3>Procter &amp; Gamble's Financial Performance</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Over the 3 months period, Procter &amp; Gamble showcased positive performance, achieving a revenue growth rate of 2.06% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Consumer Staples sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Procter &amp; Gamble's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 20.83%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Procter &amp; Gamble's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 8.99%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Procter &amp; Gamble's ROA stands out, surpassing industry averages. With an impressive ROA of 3.66%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Procter &amp; Gamble's debt-to-equity ratio is below the industry average. With a ratio of 0.69, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Procter & Gamble: Insights From 12 Analyst Reviews

Deep-pocketed investors have adopted a bullish approach towards Fortinet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in FTNT usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 22 extraordinary options activities for Fortinet. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 72% leaning bullish and 22% bearish. Among these notable options, 5 are puts, totaling $291,612, and 17 are calls, amounting to $6,744,189.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $67.5 to $115.0 for Fortinet over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Fortinet options trades today is 1575.43 with a total volume of 8,406.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Fortinet's big money trades within a strike price range of $67.5 to $115.0 over the last 30 days.
<h3>Fortinet 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740423635_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>FTNT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$33.45</td>
<td>$32.65</td>
<td>$33.2</td>
<td>$100.00</td>
<td>$2.4M</td>
<td>8.2K</td>
<td>1.3K</td>
</tr>
<tr>
<td>FTNT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$33.7</td>
<td>$31.65</td>
<td>$33.4</td>
<td>$100.00</td>
<td>$668.0K</td>
<td>8.2K</td>
<td>800</td>
</tr>
<tr>
<td>FTNT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$33.75</td>
<td>$31.95</td>
<td>$33.4</td>
<td>$100.00</td>
<td>$557.7K</td>
<td>8.2K</td>
<td>633</td>
</tr>
<tr>
<td>FTNT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$33.45</td>
<td>$33.1</td>
<td>$33.1</td>
<td>$100.00</td>
<td>$383.9K</td>
<td>8.2K</td>
<td>1.3K</td>
</tr>
<tr>
<td>FTNT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$34.0</td>
<td>$32.15</td>
<td>$34.0</td>
<td>$100.00</td>
<td>$340.0K</td>
<td>8.2K</td>
<td>0</td>
</tr>
</tbody>
</table>

<h3>About Fortinet</h3>
Fortinet is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, zero-trust access, and security operations. The firm derives a majority of its revenue through sales of its subscriptions and support-based business. The California-based firm has more than 800,000 customers across the world.
In light of the recent options history for Fortinet, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Fortinet</h3>
<ul>
<li>Currently trading with a volume of 3,369,347, the FTNT's price is down by -0.56%, now at $109.4. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 66 days.</li>
</ul>
<h3>What The Experts Say On Fortinet</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $122.4.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Baird lowers its rating to Neutral with a new price target of $112. 
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Equal-Weight rating on Fortinet with a target price of $105. 
&#x2A; An analyst from Scotiabank has decided to maintain their Sector Outperform rating on Fortinet, which currently sits at a price target of $135. 
&#x2A; An analyst from Piper Sandler has revised its rating downward to Overweight, adjusting the price target to $135. 
&#x2A; Consistent in their evaluation, an analyst from Rosenblatt keeps a Buy rating on Fortinet with a target price of $125. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Fortinet, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

FTNT

Market Whales and Their Recent Bets on FTNT Options

Deep-pocketed investors have adopted a bullish approach towards Microchip Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in MCHP usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 14 extraordinary options activities for Microchip Technology. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 42% leaning bullish and 35% bearish. Among these notable options, 10 are puts, totaling $1,126,434, and 4 are calls, amounting to $538,215.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $50.0 to $63.0 for Microchip Technology over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Microchip Technology's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Microchip Technology's substantial trades, within a strike price spectrum from $50.0 to $63.0 over the preceding 30 days.
<h3>Microchip Technology 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740423630_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MCHP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$4.2</td>
<td>$4.1</td>
<td>$4.2</td>
<td>$50.00</td>
<td>$367.0K</td>
<td>3.3K</td>
<td>984</td>
</tr>
<tr>
<td>MCHP</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$2.85</td>
<td>$2.75</td>
<td>$2.8</td>
<td>$62.50</td>
<td>$322.0K</td>
<td>7.9K</td>
<td>1.5K</td>
</tr>
<tr>
<td>MCHP</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$4.4</td>
<td>$4.0</td>
<td>$4.2</td>
<td>$50.00</td>
<td>$150.3K</td>
<td>3.3K</td>
<td>0</td>
</tr>
<tr>
<td>MCHP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/07/25</td>
<td>$1.8</td>
<td>$1.75</td>
<td>$1.75</td>
<td>$63.00</td>
<td>$131.9K</td>
<td>1.1K</td>
<td>754</td>
</tr>
<tr>
<td>MCHP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/07/25</td>
<td>$1.45</td>
<td>$1.35</td>
<td>$1.45</td>
<td>$60.00</td>
<td>$97.8K</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

<h3>About Microchip Technology</h3>
Microchip Technology became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Having examined the options trading patterns of Microchip Technology, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is Microchip Technology Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 3,960,262, with MCHP's price up by 0.1%, positioned at $61.13.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 70 days.</li>
</ul>
<h3>What Analysts Are Saying About Microchip Technology</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $69.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Piper Sandler has revised its rating downward to Overweight, adjusting the price target to $65. 
&#x2A; An analyst from Rosenblatt has decided to maintain their Buy rating on Microchip Technology, which currently sits at a price target of $90. 
&#x2A; An analyst from Keybanc has decided to maintain their Overweight rating on Microchip Technology, which currently sits at a price target of $60. 
&#x2A; An analyst from Needham has decided to maintain their Buy rating on Microchip Technology, which currently sits at a price target of $60. 
&#x2A; Maintaining their stance, an analyst from Rosenblatt continues to hold a Buy rating for Microchip Technology, targeting a price of $70. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Microchip Technology, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

MCHP

What the Options Market Tells Us About Microchip Technology

American Homes 4 Rent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMH#NYSE">AMH</a>) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $39.0, along with a high estimate of $41.00 and a low estimate of $37.00. This current average has decreased by 2.5% from the previous average price target of $40.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1740423621_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of American Homes 4 Rent among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brad Heffern</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$39.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Richard Hightower</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$37.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Adam Kramer</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$40.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Daniel Tricarico</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Perform</td>
<td>$38.00</td>
<td>-</td>
</tr>
<tr>
<td>Omotayo Okusanya</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$37.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Aaron Hecht</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$41.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Anthony Powell</td>
<td>Barclays</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$39.00</td>
<td>-</td>
</tr>
<tr>
<td>Aaron Hecht</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$41.00</td>
<td>$41.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to American Homes 4 Rent. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of American Homes 4 Rent compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
For valuable insights into American Homes 4 Rent's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/AMH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on American Homes 4 Rent analyst ratings.</a>
<h2>Delving into American Homes 4 Rent's Background</h2>
American Homes 4 Rent is a real estate investment trust primarily focused on acquiring, operating, and leasing single-family homes as rental properties throughout the United States. The company's real estate portfolio is largely comprised of single-family properties in urban markets in the Southern and Midwestern regions of the U.S. American Homes 4 Rent's land holdings also represent a sizable percentage of its total assets in terms of value. The company derives the vast majority of its income in the form of rental revenue from single-family properties through short-term or annual leases. The firm's largest geographical markets include Dallas, Texas; Indianapolis, Indiana; Atlanta, Georgia; and Charlotte, North Carolina in terms of the number of properties in each.
<h3>American Homes 4 Rent's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: American Homes 4 Rent's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -1.9%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Real Estate sector.
Net Margin: American Homes 4 Rent's net margin is impressive, surpassing industry averages. With a net margin of 28.23%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): American Homes 4 Rent's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 1.74%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): American Homes 4 Rent's ROA stands out, surpassing industry averages. With an impressive ROA of 0.94%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.7, American Homes 4 Rent adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into American Homes 4 Rent Stock: Analyst Perspectives (8 Ratings)

Throughout the last three months, 4 analysts have evaluated AMN Healthcare Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMN#NYSE">AMN</a>), offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $35.0, a high estimate of $40.00, and a low estimate of $33.00. A decline of 8.5% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1740423614_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive AMN Healthcare Services. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeffrey Silber</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$33.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>Citizens Capital Markets</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$33.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Tobey Sommer</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$40.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$34.00</td>
<td>$34.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to AMN Healthcare Services. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of AMN Healthcare Services compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of AMN Healthcare Services's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into AMN Healthcare Services's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AMN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on AMN Healthcare Services analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering AMN Healthcare Services: A Closer Look</h2>
AMN Healthcare Services is one of the largest healthcare staffing company in the United States. In 2023, it offered more than 13,000 nurses and allied healthcare full-time workers with provider clients nationwide. About two thirds of its business is generated from its temporary nursing division; the other third is generated from its physician placement and technology-backed workplace solutions divisions.
<h3>Understanding the Numbers: AMN Healthcare Services's Finances</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining AMN Healthcare Services's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 6.87% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: AMN Healthcare Services's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -25.52%, the company may face hurdles in effective cost management.
Return on Equity (ROE): AMN Healthcare Services's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -23.48%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): AMN Healthcare Services's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -7.38%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 1.49, AMN Healthcare Services adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About AMN Healthcare Services Stock

Stephens &amp; Co. analyst Jim Salera maintains Wingstop (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WING#NASDAQ">WING</a>) with a Overweight and maintains $400 price target.

Price Target

WING

Stephens & Co. Maintains Overweight on Wingstop, Maintains $400 Price Target

BTTR

Better Choice Announces SRx Health Solutions' Approval Of Acquisition; Special Meeting Slated For March 21, 2025

JP Morgan analyst Sebastiano Petti maintains Telephone and Data (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDS#NYSE">TDS</a>) with a Overweight and raises the price target from $53 to $56.

JP Morgan Maintains Overweight on Telephone and Data, Raises Price Target to $56

In the current market session, Warrior Met Coal Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCC#NYSE">HCC</a>) price is at $49.58, after a 7.48% spike. However, over the past month, the stock fell by 3.51%, and in the past year, by 15.45%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1740422716_0.png" alt="Past Year Chart" />

<h3>Warrior Met Coal P/E Compared to Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 17.16 in the Metals &amp; Mining industry, Warrior Met Coal Inc. has a lower P/E ratio of 9.65. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1740422716_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

A Look Into Warrior Met Coal Inc's Price Over Earnings

JP Morgan analyst Sebastiano Petti maintains United States Cellular (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USM#NYSE">USM</a>) with a Overweight and raises the price target from $86 to $88.

JP Morgan Maintains Overweight on United States Cellular, Raises Price Target to $88

J.P. Morgan has upgraded Amneal Pharmaceuticals, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRX#NASDAQ">AMRX</a>), noting the company&#8217;s generics business is increasingly well-positioned with a solid Crexont launch and continued momentum across the portfolio.
In August 2024, the FDA approved Amneal&#8217;s IPX203 for Parkinson&#8217;s disease as Crexont (Carbidopa and Levodopa) <a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/b40235178/amneal-receives-u-s-fda-approval-for-ipx203-for-treatment-of-parkinsons-disease-to-be-launched-as-" rel="noreferrer noopener">extended-release capsules</a>. The generic drug was <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/b40978015/amneal-launches-crexont-carbidopa-and-levodopa-extended-release-capsules-for-treatment-of-parkinso" rel="noreferrer noopener">launched in September</a>.
J.P. Morgan analyst Chris Schott reports that Crexont prescriptions are nearing 1,000 per week, with 964 recorded in the week of February 14.
The drug is capturing market share faster than expected, making up about 15% of Rytary&#8217;s volume.
Schott anticipates strong growth throughout the year as Amneal expands insurance coverage. As a result, J.P. Morgan is increasing its sales projections, forecasting Crexont revenue of $64 million in 2025, $125 million in 2026, and peak sales above $300 million, surpassing Rytary.
On February 28, Amneal is scheduled to release its <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b43301728/amneal-to-report-fourth-quarter-and-full-year-2024-results-on-february-28-2025" rel="noreferrer noopener">fourth-quarter earnings</a>.
According to data from Benzinga Pro, the generics player is expected to report fourth-quarter sales of $707.05 million and <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">adjusted EPS of 15 cents</a>.
J.P. Morgan has upgraded Amneal from Neutral to Overweight with a price forecast of $12, <a target="_blank" href="https://www.benzinga.com/quote/AMRX/analyst-ratings" rel="noreferrer noopener">up from $9</a>.
The analyst notes that Amneal has moved its generics business from simple oral tablets to more complex products, which should support long-term growth.
This shift, successful <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43810207/amneal-launches-mesalamine-and-receives-u-s-fda-approval-for-lenalidomide" rel="noreferrer noopener">new product launches</a>, and a steadier pricing environment for generics helped the company&#8217;s generics segment grow by double digits in 2024. Growth is expected to continue in 2025, with an 8% increase driven by new generics and rising biosimilar adoption.
With strong growth from generics, brand-name drugs, and AvKARE (which has grown over 20% in the past two years), JP Morgan writes, &#8220;We believe AMRX is positioned to generate growth well ahead of peers.&#8221;
Price Action: AMRX stock is up 8.75% at $8.515 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43907948/nokia-partners-with-globe-telecom-to-tackle-fraud-in-banking-with-secure-apis" target="_blank" rel="noreferrer noopener">Nokia Partners with Globe Telecom To Tackle Fraud In Banking With Secure APIs</a></li>
</ul>
Photo via Shutterstock.

Analyst Color

Equities

Guidance

Upgrades

Health Care

Movers

Trading Ideas

General

AMRX

Generic Drug Maker Amneal Pharmaceuticals Is Positioned To Growth Well Ahead Of Peers, Analyst Upgrades Stock

Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) launched new <a target="_blank" href="https://www.benzinga.com/topic/intel" rel="noreferrer noopener">Intel Xeon 6 processors</a> with Performance cores across data center workloads and up to 2 times higher performance in AI processing to meet the demands of next-generation workloads like AI and high-performing <a target="_blank" href="https://www.intc.com/news-events/press-releases/detail/1728/intel-unveils-leadership-ai-and-networking-solutions-with" rel="noreferrer noopener">and efficient computing</a>.
New Xeon 6 processors for network and edge applications with built-in Intel vRAN Boost deliver up to 2.4 times the radio access network (RAN) workload capacity.
The&nbsp;Intel&nbsp;Xeon&nbsp;6700/6500 series processor with P-cores&nbsp;is the ideal CPU for modern data centers, delivering an average of 1.4x better performance than the previous generation&nbsp;across a wide range of enterprise workloads, Xeon 6 is also the foundational central processing unit (CPU) for AI systems.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/price-target/25/02/43788975/amd-closing-competitive-gpu-gap-with-nvidia-gains-market-share-from-intel-in-client-and-server-markets-analyst" rel="noreferrer noopener">AMD Closing Competitive GPU Gap With Nvidia, Gains Market Share From Intel In Client And Server Markets: Analyst</a>
The&nbsp;Intel Xeon 6 for network and edge&nbsp;is a system-on-chip (SoC) designed for high performance and power efficiency. It leverages Intel's built-in accelerators for virtualized radio access networks (vRAN), media, AI, and network security, delivering up to 2.4x the RAN capacity7&nbsp;and a 70% improvement in performance-per-watt compared to previous generations.
As AI adoption continues to accelerate, organizations will likely spend up to $153 billion on generative AI (GenAI) by 2027, with total spending for machine learning and analytics reaching $361 billion, according to IDC.
Intel stock plunged over 43% in the last 12 months, with reports indicating Taiwan Semiconductor Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) and Broadcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) are <a target="_blank" href="https://www.benzinga.com/analyst-ratings/price-target/25/02/43792756/taiwan-semiconductors-intel-foundry-acquisition-could-be-negative-for-asml-kla-synopsys-and-cadence-analyst" rel="noreferrer noopener">considering acquiring the</a> struggling chipmaker.
Oppenheimer&nbsp;and Stifel&nbsp;noted that Intel continues to <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/43405796/intel-attempts-turnaround-analysts-remain-on-the-sidelines" rel="noreferrer noopener">lose market share</a> to&nbsp;Advanced Micro Devices, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) in its Client Computing Group and Data Center segments, prompting them to remain on the sidelines regarding a possible turnaround for the chipmaker.
Price Action: INTC stock is down 0.54% at $24.74 at last check Monday.
Next Read:
<ul>
<li><a href="https://www.benzinga.com/25/02/43917474/microsoft-cancels-major-data-center-leases-raises-questions-on-ai-expansion-strategy" target="_blank" rel="noreferrer noopener">Microsoft Cancels Some Data Center Leases, Raises Questions on AI Expansion Strategy</a></li>
</ul>
Image via Shutterstock

Tech

AVGO

INTC

Intel Unveils Xeon 6 Chips, Doubling AI Performance and Powering Next-Gen Data Centers

Shares of Constellation Energy Corporation (CEG) are trading lower Monday. This comes after Friday's sell off of more than 8%. There is a good chance <a href="https://www.benzinga.com/quote/CEG/news">the move lower continues.</a>
As you can see on the chart, the stock found support around the $280 level and rallied. Stocks rallying after they reach support is a common occurrence in the stock market. But now, this support appears to have broken. This is why Constellation Energy is our Stock of the Day.
Support is a price level where there is a large amount of buy interest.
If a stock is trending lower, it is because there are more shares for sale than there are to be bought. This forces traders and investors who wish to sell to offer their shares out at a discount, forcing the stock into a downtrend.
When a stock reaches a support level, the dynamic changes. As many, if not more, shares must be bought than sold. This is why selloffs pause or end when they reach support.
Read Also: <a href="https://www.benzinga.com/tech/25/02/43910982/apple-commits-500-billion-in-us-investment-for-ai-push-boost-us-manufacturing-tech">Apple Commits $500 Billion In US Investment For AI Push, Boost US Manufacturing Tech</a>
Sometimes, stocks rally after reaching a support level like Constellation did when it last dropped to $280. This occurs due to anxious buyers.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="549" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/24132956/ces-1024x549.png" alt="" class="wp-image-796096" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/24132956/ces-1024x549.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/24132956/ces-300x161.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/24132956/ces-768x411.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/24132956/ces.png 1512w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Some of these buyers become concerned that others will be willing to pay higher prices than they are. They know that this is who the sellers will go to.
They don't want to miss out, so they increase the prices they are willing to pay. Other concerned buyers see this and do the same thing. This can result in a snowball effect or bidding war that pushes the price higher.
But sometimes, support breaks, and the shares trade below it. This bearish dynamic shows that the buyers who created the support have left the market.
Sellers may once again be forced to lower the price if they want their orders executed, which means Constellation may trend lower.
The reason why there was support at $280 is because it had previously been a resistance level.
Levels that were resistance can turn into support. This is also a common occurrence in the market. It happens because there are people who sold at the resistance who came to regret doing so when the resistance broke and the price moved higher.
A number of these remorseful sellers decide that if they can buy their shares back at the same price they were sold for, they will. As a result, if the stock falls back to the resistance level they place buy orders. If there are enough of these orders, it will form support at the price that had been resistance.
But now that the support is broken, another move down may follow.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/02/43905646/nvidia-set-for-clear-beat-and-raise-special-as-ai-demand-surges-says-dan-ives">Nvidia Set For &#8216;Clear Beat And Raise Special&#8217; As AI Demand Surges, Says Dan Ives</a></li>
</ul>
Photo: Pitor Swat via Shutterstock

Stock Of The Day: Will Constellation Energy Keep Moving Lower?

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Mizuho cut Intra-Cellular Therapies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) price target from $140 to $132. Mizuho analyst Graig Suvannavejh downgraded the stock from Outperform to Neutral. Intra-Cellular Therapies shares closed at $128.60 on Friday. <a href="https://www.benzinga.com/quote/ITCI/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs slashed the price target for Conagra Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAG#NYSE">CAG</a>) from $33 to $26. Goldman Sachs analyst Leah Jordan downgraded the stock from Buy to Neutral. Conagra shares closed at $25.79 on Friday. <a href="https://www.benzinga.com/quote/CAG/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities cut Rivian Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) price target from $13 to $10. B of A Securities analyst John Murphy downgraded the stock from Neutral to Underperform. Rivian Automotive, shares closed at $12.97 on Friday. <a href="https://www.benzinga.com/quote/RIVN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler cut the price target for Block, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) from $101 to $85. Piper Sandler analyst Arvind Ramnani maintained an Overweight rating. Block shares closed at $68.35 on Friday. <a href="https://www.benzinga.com/quote/XYZ/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Citigroup slashed the price target for NICE Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NICE#NASDAQ">NICE</a>) from $279 to $228. Citigroup analyst Tyler Radke maintained a Buy rating. NICE shares closed at $155.39 on Friday. See how other <a href="https://www.benzinga.com/quote/NICE/analyst-ratings">analysts view this stock</a>.</li>
<li>RBC Capital cut Wayfair Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/W#NYSE">W</a>) price target from $50 to $43. RBC Capital analyst Steven Shemesh maintained a Sector Perform rating. Wayfair shares settled at $41.83 on Friday. <a href="https://www.benzinga.com/quote/W/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Loop Capital slashed Louisiana-Pacific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPX#NYSE">LPX</a>) price target from $117 to $110. Loop Capital analyst Jeffrey Stevenson maintained a Hold rating. Louisiana-Pacific shares closed at $98.71 on Friday. <a href="https://www.benzinga.com/quote/LPX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Scotiabank raised Nutrien Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTR#NYSE">NTR</a>) price target from $60 to $62. Scotiabank analyst Ben Isaacson maintained a Sector Outperform rating. Nutrien shares closed at $52.59 on Friday.  <a href="https://www.benzinga.com/quote/ntr/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies raised the price target for NIKE, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) from $75 to $115. Jefferies analyst Randal Konik upgraded the stock from Hold to Buy. Nike shares settled at $76.50 on Friday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel boosted Floor &amp; Decor Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FND#NYSE">FND</a>) price target from $100 to $110. Stifel analyst W. Andrew Carter upgraded the stock from Hold to Buy. Floor &amp; Decor shares closed at $94.27 on Friday. <a href="https://www.benzinga.com/quote/fnd/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/02/43909524/top-3-tech-stocks-that-may-crash-in-q1">Top 3 Tech Stocks That May Crash In Q1</a></li>
</ul>

ITCI

NICE

RIVN

Nike To Rally Over 50%? Here Are 10 Top Analyst Forecasts For Monday

The <a href="https://www.benzinga.com/topic/us-dollar">U.S. dollar&#8217;s recent slide</a> has less to do with trade and more with the Fed&#8217;s indifference to <a href="https://www.benzinga.com/topic/inflation">rising inflation expectations</a>, according to JPMorgan analyst Meera Chandan.
The sharp drop in U.S. real yields, fueled by the Fed's hands-off approach, has pushed the greenback lower. Chandan believes this de-risking cycle is running out of steam, with nearly 75% of the post-October dollar buying already unwound.
Read Also: <a href="https://www.benzinga.com/general/market-summary/25/02/43884153/us-services-drop-sharply-darkening-picture-of-high-prices-uncertainty-economist-says">US Services Drop Sharply: &#8216;Darkening Picture&#8217; Of High Prices, Uncertainty, Economist Says</a>
<h1 class="wp-block-heading">Yen Rally Faces Headwinds</h1>
While the yen has surged, Chandan warns that its strength may be short-lived. The Bank of Japan's policy stance, stretched speculative positioning, and significant domestic outflows could cap further gains. Policymakers are also showing discomfort with the rapid sell-off in Japanese government bonds, suggesting the yen's momentum may soon stall.
For U.S. investors looking to play this theme, the WisdomTree Japan Hedged Equity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DXJ#NYSE">DXJ</a>) offers exposure to Japanese equities while hedging yen risk.
<h1 class="wp-block-heading">China Stocks Rally, But Yuan Lags</h1>
China's AI-driven stock surge, powered by breakthroughs like Deepseek and a slower tariff rollout, has yet to lift the Chinese yuan. Unlike past rallies, JPMorgan sees limited upside for the yuan, projecting 7.40 by the second quarter and 7.50 by year-end. Solid domestic U.S. dollar demand and a smaller foreign investor footprint are keeping the yuan in check.
Investors eyeing Chinese equities without FX risk might consider the KraneShares CSI China Internet ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KWEB#NYSE">KWEB</a>).
<h1 class="wp-block-heading">JPMorgan's Playbook: Watch For A Dollar Rebound</h1>
Chandan recommends a cautious approach: stay modestly long U.S. dollars, reduce Euro shorts and take profits on Japanese yen baskets.
With the U.S. dollar's sell-off losing momentum and tariff risks still looming, JPMorgan's call is clear — the dollar's floor might be closer than markets think.
The Invesco DB US Dollar Bullish ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>) could be a practical way to position for a rebound.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43884588/alibaba-leads-china-stock-rally-as-deepseeks-ai-breakthrough-and-xis-support-boost-investor-confidence">US Listed China Stocks Rally: Alibaba&#8217;s Performance, President Xi&#8217;s Support, DeepSeek AI Boost Investor Confidence</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Currency ETFs

Forex

Global

Federal Reserve

ETFs

WisdomTree Trust Japan Total Dividend Fund

KWEB

PowerShares DB US Dollar Index Bullish Fund

Dollar Dips As Fed Holds Line, But JPMorgan Says Floor Is Near

Press Releases

WuXi Biologics Included in Hang Seng ESG 50 Index

Commodities

WuXi Biologics Receives ESG Corporate Platinum Award from The Asset for Fourth Consecutive Year

WuXi Biologics Launches WuXia™ RidGS for Non-Antibiotic Cell Line Development

WuXi Biologics Germany to Enhance Capabilities with New Prefilled Syringes Line

WuXi Biologics Achieves Major Milestones at Ireland Site with Multiple 16,000L PPQ Success and HPRA GMP Authorizations

WuXi Biologics Included in UNGC 20 Case Examples of Sustainable Development for 20 Years Collection

WuXi Biologics Ranks Top in 2024 Dow Jones Sustainability Indices for Second Consecutive Year

WuXi Biologics Announces Agreement with Candid Therapeutics on Trispecific T-cell Engager

WuXi Biologics Recognized as Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics for Fifth Consecutive Year

WuXi Biologics Awarded Platinum Medal by EcoVadis Sustainability Rating for Second Consecutive Year

WuXi Biologics (Cayman)

도널드 트럼프 대통령은 제약 회사들에게 제조를 미국으로 되돌려 놓지 않으면 관세에 직면할 것이라는 엄중한 경고를 했다고 보도되었다.
무슨 일 있었나: 금요일(21일) <a href="https://www.bloomberg.com/news/articles/2025-02-21/trump-told-drugmakers-to-move-production-to-us-or-face-tariffs">블룸버그</a> 통신에 따르면 트럼프 대통령은 비공개 회의에서 제약사들에 임박한 관세에 대해 경고하며 해외 생산을 미국으로 서둘러 이전할 것을 촉구했다.
목요일(20일)에는 일라이 릴리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) CEO인 데이비드 릭스(David Ricks), 머크(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) CEO인 로버트 데이비스(Robert Davis), 화이자(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) CEO인 앨버트 불라(Albert Bourla), 제약 산업 최대 로비 단체의 수장인 스티븐 유블(Stephen Ubl)이 백악관에서 트럼프와 만났다. 이들 경여진은 트럼프에게 연방 정부가 특정 의약품 가격을 협상할 수 있는 법안을 제한하는 노력을 지지해줄 것을 설득하고, 환자 부담 비용을 증가시키는 중개인에 대한 대책을 지지해줄 것을 요청했다.
블룸버그 보도에 따르면, 트럼프는 제약 업계가 요구해 온 조 바이든 전 대통령 재임 시절에 제정된 약가 프로그램 완화를 위해 의회를 지지하겠다고 약속하지는 않았다.
메디케어 관계자는 금요일에 약가 협상 프로그램의 다음 단계가 예정되어 있으며 노보 노디스크(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>)의 블록버스터 체중 감량 약물인 오젬픽과 웨고비가 포함될 것이라고 확인했다.
한편, 트럼프 대통령은 로버트 F. 케네디 주니어 보건복지부 장관과 그의 메디케어 및 메디케이드 서비스센터장 지명자인 메멧 오즈(Mehmet Oz)가 약가 인하를 위해 노력하고 있다고 밝혔다.
왜 중요한가: 지난주 트럼프는 미국으로 수입되는 의약품에 <a href="https://www.benzinga.com/25/02/43805852/trump-shakes-global-trade-with-25-auto-chip-and-pharma-tariffs-announcement-asian-stocks-pare-their-five-day-rally">25%의 관세를 부과</a>할 것을 제안했다. 트럼프의 이러한 최근 움직임은 제약 업계와의 이전 대립을 고려할 때 놀라운 일이 아니다. 첫 임기 동안 그는 한때 제약업계가 약값으로 &#8216;살인&#8217;하고 있다고 비난하기도 했다.
ING 은행은 미국이 2024년에 약 36%의 의약품을 수입할 것으로 추정하며, 아일랜드, 독일, 스위스가 주요 수입국으로 꼽힌다. 한편, 대서양위원회의 데이터에 따르면 미국의 중국산 의약품 수입은 2020~2022년 사이에 485% 급증한 것으로 나타났다.
최근 트럼프 대통령이 제약회사에 미국 내 생산 전환을 경고한 이후, 중국 바이오테크 주가는 오늘 아시아 거래에서 큰 타격을 입었다. 우시 바이로직스(OTC:<a class="ticker" href="https://www.benzinga.com/stock/WXXWY#OTC">WXXWY</a>), WuXi AppTec우시 앱텍(OTC:<a class="ticker" href="https://www.benzinga.com/stock/WUXAY#OTC">WUXAY</a>), 파마론 베이징(OTC:<a class="ticker" href="https://www.benzinga.com/stock/PHBBF#OTC">PHBBF</a>) 주가가 크게 하락했다.
그러나 ING는 바이든 행정부의 보고서에 따르면 용량 제한이 의약품 부족의 원인이라고 지적했기 때문에 미국 제약 제조를 확대하라는 트럼프의 요구가 정당하다고 주장했다. 하지만 워싱턴대학교의 2022년 보고서에 따르면 용량 확장에는 2~3년이 소요될 것이다.
이미지 출처: Shutterstock
면책 조항: 이 콘텐츠는 부분적으로 AI 도구의 도움을 받아 생성되었으며, Benzinga 편집자가 검토하고 게시했습니다.
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

WuXi Biologics (Cayman)

뉴스

에 대한 최신 뉴스 WuXi Biologics (Cayman) (OTC:WXXWY) 주식

월요일, 2월 24, 2025

뉴스

파트너 / 기고자

벤징가 글로벌